

“The French specialty pharmaceutical company Juvisé Pharmaceuticals has successfully completed a €400M refinancing following the acquisition of the worldwide rights of Pylera®, an antimicrobial tri-therapy indicated for gastro-intestinal *Helicobacter pylori* infections”

The French speciality pharmaceutical company, Juvisé Pharmaceuticals has recently completed a transaction with AbbVie, regarding the acquisition of the worldwide commercial rights of Pylera®. Details of this transaction remain undisclosed.

A €400 million financing was raised with Société Générale, Juvisé Pharmaceuticals historic and lead bank, supporting the funding of this latest acquisition together with the refinancing of its existing debt. Lazard and Latham & Watkins served as financial and legal advisors for Juvisé Pharmaceuticals, whereas White & Case served as legal advisors for Société Générale.

Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared « We are delighted to have successfully accomplished this transaction with AbbVie regarding Pylera®, a high-quality medicine, crucial for patients suffering from a serious gastro-intestinal disease. We were also pleased to be able to count on the permanent and unwavering support of our long-term banking partner, Société Générale »

This is another example of Juvisé Pharmaceuticals capacity to establish successful alliances with world class pharmaceuticals actors as per previous transactions concluded with Novartis and AstraZeneca. This acquisition also highlights Juvisé Pharmaceuticals strengths in deal selection and transaction execution.

About Pylera®

Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with *Helicobacter pylori* infection suffering from gastro-duodenal ulcer disease. The eradication of the pathogen agent has been shown to reduce the risk of peptic ulcers recurrence and gastric cancers.

About Juvisé Pharmaceuticals

Founded by Frederic Mascha in 2008, Juvisé Pharmaceuticals is specialised in manufacturing, distributing, and marketing its own branded pharmaceutical products. The company focuses on offering, in 80 countries around the world, original treatments in: (i) Oncology, (ii) Gastro-Enterology, (iii) Cardio-Haematology and (iv) Neuro-Psychiatry.

For more information, please visit juvisepharmaceuticals.com

Media Relations

Soline LACOUR, Chief Medical and Sales Operations, +33 1 88 40 59 27, soline.lacour@juvise.com

Investor Relations

Antoine GUILLOT, Chief Financial Officer, +33 4 26 29 40 15, antoine.guillot@juvise.com